Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 6/20 | 0.37 |
| ▸ | ACLY | P53396 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | DHODH | Q02127 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | TYK2 | P29597 | 1/20 | 0.33 |
| ▸ | MET | P08581 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | MTOR | P42345 | 1/20 | 0.31 |
| ▸ | JAK3 | P52333 | 1/20 | 0.31 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.31 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13385418 | 0.83 | ACLY (0.38) | ACLYMAPK1HTTDHODHJAK2 | |
| SCHEMBL13385419 | 0.81 | ACLY (0.37) | ACLYMAPK1HTTJAK2TYK2 | |
| SCHEMBL2837940 | 0.75 | CXCR2 (0.36) | L3MBTL1DHODHJAK2 | |
| SCHEMBL4837619 | 0.74 | HTT (0.37) | MAPTMAPK1HTTNPSR1L3MBTL1 | |
| SCHEMBL17000504 | 0.74 | ADORA2A (0.33) | ADORA2A | |
| SCHEMBL4019944 | 0.74 | IDH1 (0.36) | ADORA2AMAPTMAPK1HTTNPSR1 | |
| SCHEMBL2833335 | 0.74 | IDH1 (0.36) | ADORA2AMAPTMAPK1HTTNPSR1 | |
| SCHEMBL2833339 | 0.74 | IDH1 (0.36) | ADORA2AMAPTMAPK1HTTNPSR1 | |
| SCHEMBL13385424 | 0.74 | ACLY (0.38) | ACLYMAPK1HTTJAK2TYK2 | |
| SCHEMBL13385442 | 0.74 | ACLY (0.36) | ACLYJAK2TYK2MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7709637-B2 | 5-phenylpyrimidines, their preparation, intermediates for their preparation, and their use for controlling harmful fungi | BASF SE (DE) | 2010-05-04 | — | — | US | disclosed |
| CN-100488952-C | 5-phenyl pyridine, its preparation method and intermediate product and uses in controlling harmful fungus | BASF AG (DE) | 2009-05-20 | — | — | CN | disclosed |
| US-20070088026-A1 | 5-phenylpyrimidines, their preparation, intermediates for their preparation, and their use for controlling harmful fungi | METAVANTE CORPORATION | 2007-04-19 | — | — | US | disclosed |
| US-7153860-B2 | 5-Phenylpyrimidines, methods and intermediate products for the production thereof and use of the same for controlling pathogenic fungi | BASF AKTIENGESELLSCHAFT (DE) | 2006-12-26 | — | — | US | disclosed |
| CN-1525960-A | Lorenz Gisela | �����ɷ� | 2004-09-01 | — | — | CN | disclosed |
| US-20040116429-A1 | 5-Phenylpyrimidines, methods and intermediate products for the production thereof and use of the same for controlling pathogenic fungi | BASF SE (DE) | 2004-06-17 | — | — | US | disclosed |
| EP-1373222-A2 | 5-PHENYLPYRIMIDINE, METHODS AND INTERMEDIATE PRODUCTS FOR THE PRODUCTION THEREOF AND USE OF THE SAME FOR CONTROLLING PATHOGENIC FUNGI | BASF AKTIENGESELLSCHAFT (DE) | 2004-01-02 | — | — | EP | disclosed |
| WO-2002074753-A2 | 5-PHENYLPYRIMIDINE, METHODS AND INTERMEDIATE PRODUCTS FOR THE PRODUCTION THEREOF AND USE OF THE SAME FOR CONTROLLING PATHOGENIC FUNGI | BASF AKTIENGESELLSCHAFT (DE) | 2002-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070088026-A1 | 5-phenylpyrimidines, their preparation, intermediates for their preparation, and their use for controlling harmful fungi | DPYD, CBR3, RNGTT | ADORA2A 780/4885ACLY 2487/4885MAPT 4342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.